VONG logo

VONG
Vanguard Russell 1000 Growth Index ETF

904
Volume
3.69M
52W High
$126.83
52W Low
$79.40
50D MA
$119.84
Prev Close
$116.90
Loading...
Loading...
News
all
press releases
Should Vanguard Russell 1000 Growth ETF (VONG) Be on Your Investing Radar?
Style Box ETF report for VONG
Zacks·4d ago
News Placeholder
More News
News Placeholder
DraftKings Stock Plummeted 15% After Hours –What Is Driving Such A Selloff?
DraftKings said it is expecting fiscal year 2026 revenue to be in the range of $6.5 billion to $6.9 billion, compared to analysts’ estimates of $7.3 billion, as per data from fiscal.ai.
Stocktwits·15d ago
News Placeholder
Here's How Much You Would Have Made Owning Vanguard Russell 1000 Growth ETF Stock In The Last 15 Years
read more...
Benzinga·1mo ago
News Placeholder
Shares of VONG Now Oversold
In trading on Tuesday, shares of the Vanguard Russell 1000 Growth ETF (Symbol: VONG) entered into oversold territory, changing hands as low as $117.90 per share. We define oversold territory using...
Nasdaq News: Markets·1mo ago
News Placeholder
Here's How Much You Would Have Made Owning Vanguard Russell 1000 Growth ETF Stock In The Last 15 Years
read more...
Benzinga·2mo ago
News Placeholder
Should Vanguard Russell 1000 Growth ETF (VONG) Be on Your Investing Radar?
Style Box ETF report for VONG
Zacks·2mo ago
News Placeholder
VONG ETF Factor Report
Below is Validea's ETF fundamental report for Vanguard Russell 1000 Growth ETF (VONG). The report looks at VONG's exposure to the major investing factors including value, quality, momentum and low...
Nasdaq News: Markets·2mo ago
News Placeholder
Detailed Fundamental Analysis - VONG
Below is Validea's ETF fundamental report for Vanguard Russell 1000 Growth ETF (VONG). The report looks at VONG's exposure to the major investing factors including value, quality, momentum and low...
Nasdaq News: Markets·3mo ago
News Placeholder
Should Vanguard Russell 1000 Growth ETF (VONG) Be on Your Investing Radar?
Zacks·9mo ago
News Placeholder
Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year
In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity.
Stocktwits·1y ago
<
1
2
...
>

Latest VONG News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.